Founded in 2021 by Chief Scientist Dr. Tiger H. Tao, NeuroXess is a high-tech life science company specializing in the research, development, and commercialization of implantable flexible brain-computer interface (BCI) technologies.
With fully independent, end-to-end R&D capabilities, NeuroXess leverages its globally leading flexible BCI technologies and engineering expertise to provide advanced tools and integrated system solutions for scientific research and clinical applications.
Deeply committed to the convergence of BCI and artificial intelligence, NeuroXess is guided by the vision of “Empowering Humanity with AI, Transcending Physical Limits, and Expanding the Boundaries of Human Existence and Cognition.” Upholding the principle of “TECH FOR GOOD,” the company strives to accelerate the translation of BCI technologies into real-world applications, advance human health through technological breakthroughs, and unlock new possibilities for life.
Milestones
2019.02
Jiangxi NeuroXess Technology Co., Ltd. established
2021.07
Won the“SAIL Award”, the highest award at the World Artificial Intelligence Conference
2021.09
Zhuhai Hengqin NeuroXess Semiconductor Co., Ltd. established
2021.10
Shanghai NeuroXess Technology Co., Ltd. established
2022.01
Secured nearly 100 million in Angel & Pre-A funding
2022.07
Selected as one of MIT Technology Review's "50 Smartest Companies"
2022.09
Launched the first BCI product
2022.12
Raised hundreds million in Series A round
2023.07
Completed primate and canine animal trials
2023.12
Obtained Class II medical device registration certificatefor its digital EEG device
2024.08
Conducted the first real-time motor decoding clinical trial
2024.12
Pioneered the world's first real-time Mandarin speech decoding and synthesis clinical trial
2025.04
Completed high-precision motor decoding clinical trials
2025.07
Realized the world's first cross-regional silent language decoding and mind-controlled office software
2025.10
Initiated the nation's first and world's second long-term clinical trial of the "Triple-F" BCI
2025.12
Completed Jiangxi's first "Triple-F" BCI implant surgery
2026.01
Broke ground on the BCI "Super Factory" in Ganjiang, Jiangxi
2026.02
Released the Xesskey - a pioneeing BCI plugin
2026.06
Demonstrated cross-regional brain-controlled chess gameplay between Shanghai and Jiangxi
2026.07
Initiated GCP clinical trial and entered the NMPA Special Review Procedure for Innovative Medical Devices
Stragetic Layout
Offices
- Shanghai | Headquarters
- Ganjiang New Area | Superfactory (Production, Data, Training)
- Hengqin | Chip R&D Center
- Hong Kong | Overseas Market Center
Scientific Research Market
Clinical
Honors
Shanghai High-Tech Enterprise
Shanghai Innovative Small and Medium-Sized Enterprise
Shanghai "Specialized, Refined, Distinctive, and Innovative" SME
"Minimally Invasive Implantable High-Throughput Flexible Brain-Computer Interface Technology" won the highest award at the World Artificial Intelligence Conference — the SAIL Award
MIT Technology Review's "50 Smartest Companies" (TR50)
Shanghai Key Service Unicorn (Potential) Enterprise
China BCI Huanuo Award — Top Ten Advances Award
The 12th China (Shanghai) International Technology Fair — BCI Advanced Project Award